204 related articles for article (PubMed ID: 21211490)
1. Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP).
Sanz MA; Aledort L; Mathias SD; Wang X; Isitt JJ
Value Health; 2011 Jan; 14(1):90-6. PubMed ID: 21211490
[TBL] [Abstract][Full Text] [Related]
2. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP).
Klaassen RJ; Mathias SD; Buchanan G; Bussel J; Deuson R; Young NL; Collier A; Bomgaars L; Blanchette V
Pediatr Blood Cancer; 2012 Mar; 58(3):395-8. PubMed ID: 21910213
[TBL] [Abstract][Full Text] [Related]
4. [Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain].
López MF; Mingot ME; Valcárcel D; Vicente García V; Perrin A; Campos Tapias I
Med Clin (Barc); 2015 May; 144(9):389-96. PubMed ID: 24565604
[TBL] [Abstract][Full Text] [Related]
5. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
6. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J
J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524
[TBL] [Abstract][Full Text] [Related]
7. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials.
George JN; Mathias SD; Go RS; Guo M; Henry DH; Lyons R; Redner RL; Rice L; Schipperus MR
Br J Haematol; 2009 Feb; 144(3):409-15. PubMed ID: 19016720
[TBL] [Abstract][Full Text] [Related]
8. Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal.
Mowatt G; Boachie C; Crowther M; Fraser C; Hernández R; Jia X; Ternent L
Health Technol Assess; 2009 Sep; 13 Suppl 2():63-8. PubMed ID: 19804691
[TBL] [Abstract][Full Text] [Related]
9. Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura.
Szende A; Brazier J; Schaefer C; Deuson R; Isitt JJ; Vyas P
Curr Med Res Opin; 2010 Aug; 26(8):1893-903. PubMed ID: 20553121
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults.
Kikuchi K; Miyakawa Y; Ikeda S; Sato Y; Takebayashi T
BMC Health Serv Res; 2015 Jan; 15():2. PubMed ID: 25609557
[TBL] [Abstract][Full Text] [Related]
11. Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.
Selleslag D; Bird R; Altomare I; Giagounidis A; Janssens A; Pabinger I; Pullarkat V; Wei H; Kreuzbauer G
Eur J Haematol; 2015 Feb; 94(2):169-76. PubMed ID: 25039799
[TBL] [Abstract][Full Text] [Related]
12. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
[TBL] [Abstract][Full Text] [Related]
13. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
Chouhan JD; Herrington JD
Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
[TBL] [Abstract][Full Text] [Related]
14. [Cost per responder associated with romiplostim and rituximab treatment for adult primary immune thrombocytopenia in France].
Chiche L; Perrin A; Stern L; Kutikova L; Cohen-Nizard S; Lefrère F
Transfus Clin Biol; 2014 May; 21(2):85-93. PubMed ID: 24797790
[TBL] [Abstract][Full Text] [Related]
15. Romiplostim: a review of its use in immune thrombocytopenia.
Keating GM
Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care.
Kuter DJ; Mathias SD; Rummel M; Mandanas R; Giagounidis AA; Wang X; Deuson RR
Am J Hematol; 2012 May; 87(5):558-61. PubMed ID: 22460421
[TBL] [Abstract][Full Text] [Related]
17. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
Jamali F; Lemery S; Ayalew K; Robottom S; Robie-Suh K; Rieves D; Pazdur R
Oncology (Williston Park); 2009 Jul; 23(8):704-9. PubMed ID: 19711585
[TBL] [Abstract][Full Text] [Related]
18. Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue.
Iskedjian M; Tinmouth AT; Arnold DM; Deuson R; Isitt JJ; Mikhael J
J Med Econ; 2012; 15(2):313-31. PubMed ID: 22136485
[TBL] [Abstract][Full Text] [Related]
19. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.
Tarantino MD; Despotovic J; Roy J; Grainger J; Cooper N; Beam D; Raj A; Maschan A; Kim J; Eisen M
Pediatr Blood Cancer; 2020 Nov; 67(11):e28630. PubMed ID: 32902132
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.
Lee D; Thornton P; Hirst A; Kutikova L; Deuson R; Brereton N
Appl Health Econ Health Policy; 2013 Oct; 11(5):457-69. PubMed ID: 23857462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
